Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
GPCR Stock Chart & Stats
$53.48
-$0.32(-1.18%)
At close: 4:00 PM EST
$53.48
-$0.32(-1.18%)
Day’s Range― - ―
52-Week Range$13.22 - $94.90
Previous CloseN/A
Volume219.80K
Average Volume (3M)967.89K
Market Cap
$3.79B
Enterprise Value$2.29B
Total Cash (Recent Filing)$1.45B
Total Debt (Recent Filing)$6.49M
Price to Earnings (P/E)31.2
Beta1.30
Next Earnings
May 07, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding70,841,810
10 Day Avg. Volume1,063,212
30 Day Avg. Volume967,895
Financial Highlights & Ratios
PEG Ratio-11.37
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-18.23
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.33K
Enterprise Value/Ebitda-14.47
Forecast
1Y Price Target
$108.34Price Target Upside102.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-1.52
Revenue Forecast (FY)$7.14M
Bulls Say, Bears Say
Bulls Say
Commercial And Strategic PositioningLow manufacturing costs, scalable production, and a broader pipeline increase the company's appeal to larger biopharma partners and strengthen the commercial case for an oral obesity franchise.
Efficacy And DurabilityClinical trial data indicate aleniglipron sustains progressive weight loss without a clear plateau, supporting potential durable efficacy versus competing oral therapies and the possibility of injectable-like outcomes.
Tolerability And Dosing StrategyOpen-label and extension studies show that starting at a low dose with slow upward titration lowers nausea and reduces treatment discontinuations, suggesting improved tolerability that could enhance real-world adherence.
Bears Say
Business Development RiskAbsence of business development activity ahead of a potential Phase 3 start could leave the company without strategic partners and limit resources for later-stage development and commercialization.
Clinical And Regulatory UncertaintyLimited patient numbers in available studies and similar efficacy across dose arms create uncertainty around optimal dosing and pivotal trial design, raising the risk of unexpected Phase 3 outcomes.
Competitive LandscapeHigh-potency injectable therapies retain a mechanistic advantage and are likely to remain market leaders, which could constrain early market share and pricing power for oral competitors.
Structure Therapeutics, Inc. Sponsored ADR News
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $13.22 and its highest was $94.90 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $3.79B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is May 07, 2026 which is in 32 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Feb 26, 2026. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of -$0.057 by $0.227.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.35.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 70,841,810 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of $0.17 in its last earnings report, beating expectations of -$0.057. Following the earnings report the stock price went down -2.734%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$108.34 (102.58% Upside)
$108.34 (102.58% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 57.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 9.5%
Last 30 Days ▲ 9.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
217.73%
12-Months-Change
Fundamentals
Return on Equity
-14.55%
Trailing 12-Months
Asset Growth
75.34%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
GPCR Stock 12 Month Forecast
Average Price Target
$108.34
▲(102.58% Upside)
Technical Analysis
Ownership Overview
9.06% Insiders
22.25% Mutual Funds
45.15% Other Institutional Investors
21.49% Public Companies and Individual Investors